** Telehealth firm Hims & Hers Health's shares rise 1.23% to $27.23 premarket

** Brokerage BTIG starts coverage with buy rating, PT $35

** Says co is "disrupting healthcare with tech and convenience"

** Unlike pure tele-health platforms that rely on remote visits, HIMS offers access to medications and treatment plans, so company is better insulated from the risk of more people returning to in-person visits - brokerage

** BTIG estimates that over 50% of HIMS' members have a personalized treatment plan

** Expects revenue growth and demand for GLP-1 and other obesity health products to remain robust

** We believe compounding for GLP-1s is here to stay - BTIG

** HIMS offers compounded versions of Novo Nordisk's

Wegovy and Ozempic

** Stock more than doubled last year

(Reporting by Sriparna Roy)